- Home
- ZYME vs PRSU Comparison
ZYME vs PRSU Comparison
Compare ZYME & PRSU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZYME
- PRSU
- Stock Information
- Founded
- ZYME 2003
- PRSU 1926
- Country
- ZYME United States
- PRSU United States
- Employees
- ZYME N/A
- PRSU N/A
- Industry
- ZYME Biotechnology: Pharmaceutical Preparations
- PRSU Business Services
- Sector
- ZYME Health Care
- PRSU Consumer Discretionary
- Exchange
- ZYME Nasdaq
- PRSU Nasdaq
- Market Cap
- ZYME 968.5M
- PRSU 999.2M
- IPO Year
- ZYME 2017
- PRSU N/A
- Fundamental
- Price
- ZYME $15.93
- PRSU $36.32
- Analyst Decision
- ZYME Buy
- PRSU Strong Buy
- Analyst Count
- ZYME 7
- PRSU 3
- Target Price
- ZYME $20.00
- PRSU $29.67
- AVG Volume (30 Days)
- ZYME 446.6K
- PRSU 192.3K
- Earning Date
- ZYME 10-30-2025
- PRSU 11-15-2025
- Dividend Yield
- ZYME N/A
- PRSU N/A
- EPS Growth
- ZYME N/A
- PRSU 1138.43
- EPS
- ZYME N/A
- PRSU 9.98
- Revenue
- ZYME $122,867,000.00
- PRSU $382,378,000.00
- Revenue This Year
- ZYME $107.76
- PRSU $22.00
- Revenue Next Year
- ZYME $2.35
- PRSU $8.35
- P/E Ratio
- ZYME N/A
- PRSU $3.64
- Revenue Growth
- ZYME 95.94
- PRSU 4.63
- 52 Week Low
- ZYME $9.03
- PRSU $26.66
- 52 Week High
- ZYME $17.70
- PRSU $47.49
- Technical
- Relative Strength Index (RSI)
- ZYME 64.90
- PRSU 55.29
- Support Level
- ZYME $14.88
- PRSU $35.74
- Resistance Level
- ZYME $16.37
- PRSU $37.53
- Average True Range (ATR)
- ZYME 0.65
- PRSU 0.89
- MACD
- ZYME 0.11
- PRSU -0.27
- Stochastic Oscillator
- ZYME 84.12
- PRSU 22.57
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
About PRSU Pursuit Attractions and Hospitality Inc. Common Stock
Pursuit Attractions and Hospitality Inc is an attractions and hospitality company that owns and operates a collection of inspiring and unforgettable experiences at iconic destinations across the United States, Canada, and Iceland. Its elevated hospitality offerings include point-of-interest attractions and distinctive lodges, as well as integrated restaurants, retail options, and transportation that allow visitors to discover and connect with breathtaking national parks and renowned travel locations.